Format

Send to

Choose Destination
Proc IEEE Int Symp Biomed Imaging. 2018 Apr;2018:796-799. doi: 10.1109/ISBI.2018.8363692. Epub 2018 May 24.

A METHOD FOR QUANTIFICATION OF CALPONIN EXPRESSION IN MYOEPITHELIAL CELLS IN IMMUNOHISTOCHEMICAL IMAGES OF DUCTAL CARCINOMA IN SITU.

Author information

1
Department of Biomedical Engineering and Computational Biology Program.
2
Department of Cell, Developmental and Cancer Biology Oregon Health & Science University.

Abstract

Ductal carcinoma in situ (DCIS) is breast cancer confined within mammary ducts, surrounded by an intact myoepithelial cell layer that prevents local invasion. A DCIS diagnosis confers increased lifetime risk of developing invasive breast cancer (IBC) and results in surgical excision with radiation, and possibly endocrine- or chemo-therapy. DCIS is known to be over treated, with associated co-morbidities. Biomarkers are needed that delineate patients at low risk of DCIS progression from patients requiring more aggressive treatment. Investigating the role of myoepithelial cell differentiation in barrier function is anticipated to provide insight into DCIS progression and delineate between low and high risk lesions. Here, we develop a high throughput technique to assess loss of myoepithelial differentiation markers. This method facilitates automated analysis of a clinically relevant histopathologic feature, as demonstrated by a high correlation with pathologist annotation (r = 0.959), and further, contributes analytical foundations to a multiplexed immunohistochemistry (IHC) approach.

KEYWORDS:

DCIS; calponin; feature engineering; invasive breast cancer; myoepithelial cell

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center